查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592042

肾癌药物市场：按类型、药物类别、治疗层级- 全球预测 2025-2030

Kidney Cancer Drugs Market by Type (Chromophobe, Clear Cell, Collecting Duct), Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies), Therapeutic Class - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肾癌药物市场价值为58亿美元，预计到2024年将达到61.4亿美元，复合年增长率为5.97%，到2030年将达到87.1亿美元。

肾癌治疗市场由肾癌药物治疗的范围和应用定义，主要集中在生物製药、小分子抑制剂和免疫疗法。由于老年人口不断增加以及吸烟和肥胖等与生活方式相关的风险，全球肾癌发病率不断上升，凸显了对这些药物的需求。治疗方法包括标靶治疗、免疫疗法和化疗，通常用作第一线或辅助性治疗。最终用途范围主要包括依赖这些药物来提高病患存活率和生活品质的医院、癌症研究机构和专科诊所。

主要市场统计
基准年[2023] 58亿美元
预测年份 [2024] 61.4亿美元
预测年份 [2030] 87.1亿美元
复合年增长率（%） 5.97%

市场成长主要是由大量研究投资推动的，这些投资专注于早期检测生物标记的进步、联合治疗的开发和个人化医疗。最新的机会出现在扩大区域市场中，这些市场的医疗保健服务正在改善，癌症意识也在提高。研发策略联盟以及利用人工智慧进行药物发现可以进一步增加市场占有率。然而，市场面临治疗成本高、法律规范严格以及肾癌药物潜在副作用等阻碍患者依从性的限制。此外，来自生物相似药的竞争为市场现有企业带来了挑战。

基因治疗、用于药物传输的生物分解性奈米颗粒以及天然化合物衍生物的寻找等领域具有创新潜力。专注于基于基因分析的精准医疗以实现个人化治疗方法是业务成长的关键领域。总体而言，市场竞争激烈且充满活力，持续的研究和临床试验塑造了其未来的发展轨迹。希望利用市场机会的公司应专注于策略联盟、持续创新和扩大研究管道以保持竞争力。加强病患教育和支持计画在克服市场挑战方面也发挥着重要作用。

市场动态：揭示快速发展的肾癌药物市场的关键市场洞察

供需的动态交互作用正在改变肾癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 癌症患者急剧增加
    • 患有高血压和糖尿病的老年人口不断增加
    • 生活方式改变增加，包括吸烟、饮酒和吃加工食品
  • 市场限制因素
    • 与治疗相关的併发症的风险
  • 市场机会
    • 新药的供应和强大的管道的存在
    • 加大研发投入及厂商合作
  • 市场挑战
    • 严格的监理政策

波特五力：驾驭肾癌药物市场的策略工具

波特五力是了解肾臟癌药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对肾癌药物市场的影响

外部宏观环境因素在塑造肾癌治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肾癌治疗药物市场的竞争状况

肾癌治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

肾癌治疗市场供应商的 FPNV 定位矩阵绩效评估

FPNV 定位矩阵是评估肾癌药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製肾癌治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对肾癌治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症患者增加
      • 患有高血压和糖尿病的老年人越来越多
      • 生活方式的改变增加，例如吸烟、饮酒和吃加工食品
    • 抑制因素
      • 与治疗相关的併发症的风险
    • 机会
      • 新药的供应和强大的管道的存在
      • 增加研发投入以及製造商之间的合作
    • 任务
      • 严格的监理政策
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肾癌治疗药物市场：依类型

  • 恐色症
  • 透明细胞
  • 收集管
  • 癌细胞
  • 乳头状的

第七章依药理类别分類的肾癌治疗药物市场

  • 血管新生抑制剂
  • 细胞激素免疫治疗
  • 单株抗体
  • MTOR抑制剂

第八章依治疗层级的肾癌治疗药物市场

  • 免疫疗法
  • 标靶治疗

第九章 美洲肾癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区肾癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲肾癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Prometheus Laboratories Inc.
  • Sun Pharmaceutical Industries Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA0527F

The Kidney Cancer Drugs Market was valued at USD 5.80 billion in 2023, expected to reach USD 6.14 billion in 2024, and is projected to grow at a CAGR of 5.97%, to USD 8.71 billion by 2030.

The kidney cancer drugs market is defined by the scope and application of pharmaceutical treatments for renal cancers, primarily focusing on biologics, small-molecule inhibitors, and immunotherapies. The necessity for these drugs is underscored by the rising incidence of kidney cancer globally, driven by factors such as increasing geriatric population and lifestyle-related risks like smoking and obesity. Applications span targeted therapy, immunotherapy, and chemotherapy, often employed as first-line or adjuvant treatments. The end-use scope predominantly includes hospitals, cancer research institutes, and specialty clinics, which rely on these drugs to improve survival rates and quality of life for patients.

KEY MARKET STATISTICS
Base Year [2023] USD 5.80 billion
Estimated Year [2024] USD 6.14 billion
Forecast Year [2030] USD 8.71 billion
CAGR (%) 5.97%

Market growth is significantly influenced by advancements in biomarkers for early detection, the development of combination therapies, and substantial research investments focusing on personalized medicine. The latest opportunities are found in expanding geographic markets where increasing healthcare access and rising cancer awareness are prevalent. Strategic collaborations for R&D and leveraging artificial intelligence for drug discovery can further enhance market presence. However, the market faces limitations such as high treatment costs, stringent regulatory frameworks, and potential side effects of kidney cancer drugs, which can hinder patient compliance. Additionally, competition from biosimilars poses a challenge to market incumbents.

Innovation can thrive in the areas of gene therapy, biodegradable nanoparticles for drug delivery, and the exploration of natural compound derivatives. Emphasizing precision medicine based on genetic profiling to personalize treatment options presents a key area for business growth. Overall, the market is highly competitive and dynamic, with ongoing research and clinical trials shaping its future trajectory. Companies aiming to capitalize on market opportunities should focus on strategic alliances, continuous innovation, and expanding their research pipeline to maintain a competitive edge. Enhanced patient education and support programs can also play a crucial role in overcoming market challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Kidney Cancer Drugs Market

The Kidney Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Proliferation in the number of people suffering from cancer
    • Growing geriatric population with hypertension and diabetes
    • Increasing lifestyle changes including smoking, drinking, and consumption of processed food
  • Market Restraints
    • Risk of complications associated with treatment
  • Market Opportunities
    • Availability of novel drugs and the presence of a strong pipeline
    • Increasing research and development investment coupled with collaborations among manufacturers
  • Market Challenges
    • Stringent regulatory policies

Porter's Five Forces: A Strategic Tool for Navigating the Kidney Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Kidney Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Kidney Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Kidney Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Kidney Cancer Drugs Market

A detailed market share analysis in the Kidney Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Kidney Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Kidney Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Kidney Cancer Drugs Market

A strategic analysis of the Kidney Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Kidney Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen, Inc., AVEO Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Genentech, Inc., GlaxoSmithKline PLC, NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., Novartis AG, Pfizer Inc., Prometheus Laboratories Inc., Sun Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Kidney Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chromophobe, Clear Cell, Collecting Duct, Oncocytic, and Papillary.
  • Based on Pharmacologic Class, market is studied across Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies, and MTOR Inhibitors.
  • Based on Therapeutic Class, market is studied across Immunotherapy and Targeted Therapy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Proliferation in the number of people suffering from cancer
      • 5.1.1.2. Growing geriatric population with hypertension and diabetes
      • 5.1.1.3. Increasing lifestyle changes including smoking, drinking, and consumption of processed food
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of complications associated with treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of novel drugs and the presence of a strong pipeline
      • 5.1.3.2. Increasing research and development investment coupled with collaborations among manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Kidney Cancer Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Chromophobe
  • 6.3. Clear Cell
  • 6.4. Collecting Duct
  • 6.5. Oncocytic
  • 6.6. Papillary

7. Kidney Cancer Drugs Market, by Pharmacologic Class

  • 7.1. Introduction
  • 7.2. Angiogenesis Inhibitors
  • 7.3. Cytokine Immunotherapy
  • 7.4. Monoclonal Antibodies
  • 7.5. MTOR Inhibitors

8. Kidney Cancer Drugs Market, by Therapeutic Class

  • 8.1. Introduction
  • 8.2. Immunotherapy
  • 8.3. Targeted Therapy

9. Americas Kidney Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Kidney Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Kidney Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen, Inc.
  • 2. AVEO Pharmaceuticals, Inc.
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Eisai Co., Ltd.
  • 6. Exelixis, Inc.
  • 7. Genentech, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. NanoString Technologies, Inc.
  • 10. NeoGenomics Laboratories, Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Prometheus Laboratories Inc.
  • 14. Sun Pharmaceutical Industries Limited
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. KIDNEY CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. KIDNEY CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. KIDNEY CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. KIDNEY CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023